⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BNTC News
Benitec Biopharma Inc. Common Stock
Form 8-K
sec.gov
BNTC
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
globenewswire.com
BNTC
Form 8-K
sec.gov
BNTC
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
globenewswire.com
BNTC
Form 8-K
sec.gov
BNTC
Form 8-K
sec.gov
BNTC
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
globenewswire.com
ALNY
ARWR
SLN
BNTC
Form 8-K
sec.gov
BNTC
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
globenewswire.com
BNTC
Form 8-K
sec.gov
BNTC